Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Some fat is essential for body function

It's common knowledge that too much cholesterol and other fats can lead to disease, and that a healthy diet involves watching how much fatty food we eat. However, our bodies need a certain amount of fat to function—and we can't make it from scratch.

14 Feb 2011

Researchers discover mechanism for normalizing blood sugar without insulin need

Diabetes can result from either a deficiency of insulin or decreased sensitivity to insulin. Researchers at Children's Hospital Boston have discovered a mechanism for normalizing blood sugar that doesn't involve insulin and could offer a new therapeutic approach to both kinds of diabetes.

14 Feb 2011

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome and acute lung injury in individuals with type II diabetes, according to a study conducted by researchers in Chicago.

13 Feb 2011

Study sheds new light on riboswitch that turns genes on or off in response to cell's energy needs

Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.

13 Feb 2011

Dyadic issued seventh U.S. patent

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").

11 Feb 2011

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Inhibitex, Inc. today reported that the U.S. Food and Drug Administration ("FDA") has designated the investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral infection, as a Fast Track development program.

11 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

11 Feb 2011

New perspectives challenge long-held beliefs about impact of saturated fatty acids on risk of cardiovascular disease

For generations, the consumption of dairy products has been positively associated with the health and wellness of families and communities. Nevertheless, the recent shift in dietary trends has focused on "what not to eat" instead of emphasizing "what to eat," resulting in demonizing the naturally occurring fats in dairy, while overlooking its many essential nutrients.

11 Feb 2011

Viral infection of Leishmania leads to increased pathogenicity

A parasite and a virus may be teaming up in a way that increases the parasite's ability to harm humans, scientists at the University of Lausanne in Switzerland and Washington University School of Medicine in St. Louis report this week in Science.

11 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

UC Santa Barbara scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes. Their work is published in a recent issue of Nature Chemistry.

10 Feb 2011

DOPAL plays key role in killing dopamine neurons which trigger Parkinson's disease: Study

In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Phospholipid membranes demonstrate ability to absorb lanthanum cations

University of Granada scientists and the Spanish Higher Institute for Scientific Research (CSIC) have made significant progress in understanding lipid membranes, which are extensively employed in the development of cosmetic and drug products, and which have potential application in the field of nanotechnology.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Protein News and Research

Further Reading

Phase III RISE study of Lucentis for DME meets primary endpoint

Some fat is essential for body function

Researchers discover mechanism for normalizing blood sugar without insulin need

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Study sheds new light on riboswitch that turns genes on or off in response to cell's energy needs

Dyadic issued seventh U.S. patent

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Blocking interleukin 15 may help restore oral tolerance to gluten

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

New perspectives challenge long-held beliefs about impact of saturated fatty acids on risk of cardiovascular disease

Viral infection of Leishmania leads to increased pathogenicity

Scientists develop novel treatment strategy for multiple myeloma

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

DOPAL plays key role in killing dopamine neurons which trigger Parkinson's disease: Study

Full genetic blueprint of multiple prostate tumors laid bare

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

Vical 2010 net loss increases to $30.4 million

Phospholipid membranes demonstrate ability to absorb lanthanum cations

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News